Omnicell (FRA:OC9) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OC9 Omnicell Inc FRA:OC9
76 GF Score
Price €39.80
GF Value €33.66
! 7 Warning Signs
View Full Analysis

What is Omnicell SpecialCharges?

Special Charges only applies to banks.

FRA:OC9
76GF Score
Omnicell Inc FRA:OC9
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Omnicell (FRA:OC9) Overvalued in 2026?

Based on GuruFocus' analysis, Omnicell stock appears to be overvalued. The current stock price of €39.80 is trading 18.2% above its estimated GF Value™ of €33.66.

Key valuation signals for FRA:OC9:

  • SpecialCharges:
  • GF Value™: €33.66 vs. price of €39.80 (18.2% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the FRA:OC9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Omnicell Business Description

Other Exchanges OMCL:USAOMCL:Mexico
Address 4220 North Freeway, Fort Worth, TX, USA, 76137
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
76GF Score

Get the complete analysis for FRA:OC9

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€39.80
Price
€33.66
GF Value